Our Mission is harnessing the power of Artificial Intelligence to create therapeutic molecular breakthroughs for the treatment of neurodegenerative diseases, with focus on Parkinson’s Disease, associated dementia, and Alzheimer’s Disease.
Our Mission is harnessing the power of Artificial Intelligence to create therapeutic molecular breakthroughs for the treatment of neurodegenerative diseases, with focus on Parkinson’s Disease, associated dementia, and Alzheimer’s Disease.
Both Parkinson’s Disease and Parkinson’s Disease Dementia are more common with increasing age.
24 to 80% of people with Parkinson’s Disease develop Dementia within 10 years of diagnosis.
Better treatments are needed for Parkinson’s Disease and Alzheimer’s Disease.
There is a significant impact on patient quality of life with neurodegenerative disease progression.
Parkinson’s Disease and Parkinson’s Disease Dementia
Targeting α Synuclein aggregation pathology
REM behavioral Disorder
Targeting α Synuclein aggregation pathology
Lewy Body Dementia
Targeting α Synuclein aggregation pathology
Alzheimer’s Disease
α-syn and tau proteins aggregate abnormally in AD patients
Harvard Medical School (Masters Medical Science and Clinical Investigation Graduate Degree 2023)
University of South Florida BS/BA Chemistry, Cell Biology
Over 25 years biotech research and development, and FDA product approval experience in neurodegenerative diseases, cell therapy, oncology, and anti-infectives, while holding leadership positions at Pfizer, Dendreon Oncology, Merck KGaA, and Ra Biopharma.
M.S. Business Analytics, University of Cincinnati
B.S.E. Electrical and Computer Engineering, Grand Valley State University
Over 9 years hands-on experience in engineering, Machine Learning, and Artificial Intelligence.
PhD. in Neuroscience, University of Leeds, UK
Over 20 years experience leading preclinical drug discovery programs for Neuroscience indications at Pfizer and Sage Therapeutics.
Doctorate of Pharmacy (PharmD) and B.S. in Psychology, University of Michigan
20 years experience as a bio-pharmaceutical professional. Ahmad currently serves on the Board of Governors for University of Michigan College of Pharmacy and on the Board of Directors for Lazarex Cancer Foundation.
Success to fulfill our mission will depend on partnerships with biopharma, academia, and Artificial Intelligence technology, and investors seeking new opportunities. If you are one of the above and interested in collaborating, please make sure to reach out using the form below or [email protected]
